Insmed Incorporated

Insmed Incorporated is a biotechnology company focused on developing and commercializing therapies for patients with serious and rare diseases globally. Its only approved product is ARIKAYCE, used for the treatment of refractory nontuberculous mycobacterial lung infections. The company has a robust pipeline, including brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1) in phase 3 trials for bronchiectasis and phase 2 trials for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. It is also developing treprostinil palmitil inhalation powder for pulmonary hypertension associated with interstitial lung disease (phase 3) and pulmonary arterial hypertension (phase 2). Additionally, Insmed is working on gene therapies such as INS1201 for Duchenne muscular dystrophy (phase 1) and preclinical programs in gene therapy, AI-driven protein engineering, and synthetic rescue.

Insmed Incorporated is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol INSM. Its shares are traded in United States Dollars (USD). As a US-based company, it is subject to the regulatory framework of the US Securities and Exchange Commission and reports its financial results in USD.

Insmed operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes, organisms, or cellular systems to develop products and technologies for healthcare. Insmed focuses on serious and rare diseases, leveraging both small molecules and advanced therapies like gene therapy and AI-driven protein engineering to address unmet medical needs.

Insmed Incorporated is headquartered in the United States, as indicated by its country and region classification. The company serves a global market, developing and commercializing therapies for patients with serious and rare diseases worldwide. Its approved product ARIKAYCE is available for refractory nontuberculous mycobacterial lung infections, and its pipeline targets conditions such as bronchiectasis, pulmonary hypertension, and Duchenne muscular dystrophy, indicating a broad international patient focus.

Insmed's pipeline includes several promising candidates. Brensocatib, an oral DPP1 inhibitor, is in phase 3 trials for bronchiectasis and phase 2 trials for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. Treprostinil palmitil inhalation powder is in phase 3 for pulmonary hypertension associated with interstitial lung disease and phase 2 for pulmonary arterial hypertension. INS1201, a microdystrophin gene therapy, is in phase 1 for Duchenne muscular dystrophy. Additionally, INS1148, a monoclonal antibody targeting stem cell factor, is in phase 2 for interstitial lung disease and asthma. Preclinical programs include gene therapy, AI-driven protein engineering, and synthetic rescue technologies.